Can a second-line drug help CML patients stay cancer-free without daily pills?
NCT ID NCT01774630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once more. The goal was to measure how many patients remained relapse-free three years after starting nilotinib.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Valence
Valence, 26953, France
-
CH d'Annecy
Pringy, 74374, France
-
CHU Angers
Angers, 49033, France
-
CHU de Nice, Service Hématologie Clinique
Nice, 06202, France
-
CHU de Toulouse, Service d'Hématologie
Toulouse, 31059, France
-
Centre Hospitalier Lyon Sud, Service Hématologie
Pierre-Bénite, 69495, France
-
Centre Hospitalier de Versailles - Hôpital André Mignot - Service de Médecine B
Le Chesnay, 78157, France
-
Hôpital Haut Lévêque, Service Hématologie
Pessac, 33604, France
-
Hôpital Pontchaillou
Rennes, 35033, France
-
Institut Bergonié
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.